Kellie's practice involves US and foreign patent prosecutions in biotechnology and pharmaceutical areas. Kellie also assists in patent litigations, including developing legal strategy and preparing expert reports.
Kellie prosecutes and investigates diverse technologies including: vaccines, genes and gene expression systems, proteins, antibodies, pharmaceutical formulations, methods of treatment with pharmaceuticals, and animal models. Recent Speaking Engagements and Publications
· "Biomedical Diagnostic Patents Post-Prometheus," co-author, Edwards Wildman Palmer LLP Client Advisory, March 2012.
· "Mechanistic differences in RNA-dependent DNA polymerization and fidelity between murine leukemia virus and HIV-1 reverse transcriptases," co-author, Journal of Biological Chemistry, 2005.
· "A role for dNTP binding of human immunodeficiency virus type 1 reverse transcriptase in viral mutagenesis," co-author, Biochemistry, 2004.
· "Mechanistic understanding of an altered fidelity simian immunodeficiency virus reverse transcriptase mutation, V148I, identified in a pig-tailed macaque," co-author, Journal of Biological Chemistry, 2003.
· "Mechanistic role of residue Gln151 in error prone DNA synthesis by human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). Pre-steady state kinetic study of the Q151N HIV-1 RT mutant with increased fidelity," co-author, Journal of Biological Chemistry, 2003.
· "Molecular architecture of the mutagenic active site of human immunodeficiency virus type 1 reverse transcriptase: roles of the beta 8-alpha E loop in fidelity, processivity, and substrate interactions," co-author, Biochemistry, 2000.
News & Publications
March 21, 2012, Client Advisory - Biomedical Diagnostic Patents Post-Prometheus
Before Edwards Wildman
After receiving her Ph.D. in Microbiology and Immunology in 2003, Dr. DiNapoli remained at the University of Rochester School of Medicine and Dentistry as a postdoctoral fellow in the laboratory of Dr. Robert Quivey and characterized the enzymatic activity of an apurinic/apyrimidinic endonuclease in Streptococcus mutans.
In 2004, she became a Medical Technologist at the NIH Clinical Center's Department of Laboratory Medicine where she processed and analyzed patient samples to identify clotting abnormalities.
In 2005, Dr. DiNapoli joined a Washington DC law firm as a Student Associate, became a patent agent in 2007 and an attorney in 2008.
Industries
· Life Sciences
Memberships
· American Bar Association